

**PB 22 of 2025**

National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 24 February 2025

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 March 2025 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 August 2025 14

National Health (Minimum Stockholding) Determination 2023 14

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 2) 2025*.

 (2) This instrument may also be cited as PB 22 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 March 2025. | 1 March 2025 |
| 2. Schedule 1 | 1 March 2025. | 1 March 2025 |
| 3. Schedule 2 | 1 August 2025. | 1 August 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 March 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand(b) after 31 December 2023—5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | APX-Amitriptyline | 5 months stock by reference to usual demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX‑Amitriptyline | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand(b) after 31 December 2023—4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand(b) after 31 December 2023—4.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APX‑Amitriptyline | 4.5 months stock by reference to usual demand |
| Amitriptyline | Tablet containing amitriptyline hydrochloride 50 mg | Oral | ENTRIP | 4.5 months stock by reference to usual demand |

3 Schedule 1 (table item dealing with the drug Codeine, column number 4)

Omit “Aspen Pharma Pty Ltd”, substitute “Aspen Pharmacare Australia Pty Ltd”.

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX‑Doxycycline | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand(b) after 31 December 2023—5.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX‑Doxycycline | 5.5 months stock by reference to usual demand |

5 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand(b) after 31 December 2023—2 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Enalapril | Tablet containing enalapril maleate 5 mg | Oral | Acetec | 2 months stock by reference to usual demand |

6 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | 3.5 months stock by reference to usual demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |

9 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Galantamine | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | Galantyl | 1.5 months stock by reference to usual demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Irbesartan | Tablet 150 mg | Oral | Irbesartan GH | between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand |
| Irbesartan | Tablet 300 mg | Oral | Irbesartan GH | between 1 November 2024 and 28 February 2025—0 months stock by reference to usual demand |

11 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—4.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO‑Lansoprazole ODT | 4.5 months stock by reference to usual demand |

12 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Letrozole | Tablet 2.5 mg | Oral | Letrozole APOTEX | 4 months stock by reference to usual demand of both Letrozole APOTEX and ARX-LETROZOLE added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |
| Levetiracetam | Tablet 250 mg | Oral | Levetiracetam Viatris | after 31 June 2025—4 months stock by reference to usual demand of both Levetiracetam Viatris and Levetiracetam Mylan added together |

13 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Chemists' Own Macrogol with Electrolytes | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |

14 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nicorandil | Tablets 10 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |

15 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—2 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Nicorandil | Tablets 20 mg, 60 | Oral | Ikotab | 2 months stock by reference to usual demand |

16 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | PRYZEX ODT | 3.5 months stock by reference to usual demand |

17 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMERTAN | 3.5 months stock by reference to usual demand |

18 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO‑Pantoprazole | 5.5 months stock by reference to usual demand |

19 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | 5.5 months stock by reference to usual demand |

20 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | (a) between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand (b) after 31 December 2023—2.5 months stock by reference to usual demand |

21 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Periciazine | Tablet 2.5 mg | Oral | Neulactil | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | Indosyl Mono 2 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | Indosyl Mono 4 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | Indosyl Mono 8 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Indosyl Combi 4/1.25 | between 1 March 2025 and 30 April 2025—0 months stock by reference to usual demand |
| Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | Perindo Combi 4/1.25 | 2.5 months stock by reference to usual demand |

22 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pregabalin | Capsule 150 mg | Oral | Cipla Pregabalin | between 1 October 2024 and 28 February 2025—0 months stock by reference to usual demand |

23 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Capsule 10 mg | Oral | APX‑Ramipril | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | (a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand (b) after 31 December 2023—5.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril | Capsule 10 mg | Oral | APX‑Ramipril | 5.5 months stock by reference to usual demand |
| Ramipril | Capsule 10 mg | Oral | Prilace | 5.5 months stock by reference to usual demand |

24 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | (a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand (b) after 31 December 2023—3.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Risperidone | Tablet 3 mg | Oral | APO‑Risperidone | 3.5 months stock by reference to usual demand |

25 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | (a) between 1 July 2023 and 31 December 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Roxithromycin | Tablet 300 mg | Oral | APX‑Roxithromycin | 5 months stock by reference to usual demand |

26 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | (a) between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand (b) after 31 December 2023—1.5 months stock by reference to usual demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | Cardol | 1.5 months stock by reference to usual demand |

27 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | after 30 November 2024—0 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | after 30 November 2024—0 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000) | Oral | Valine 1000 | 0 months stock by reference to usual PBS demand |
| Valine with carbohydrate | Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50) | Oral | Valine 50 | 0 months stock by reference to usual PBS demand |

Schedule 2—Amendments commencing 1 August 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciclosporin | Oral liquid 100 mg per mL, 50 mL | Oral | Neoral | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the Ear | Ciloxan | 6 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Methoxyflurane | Liquid for inhalation 999 mg per g, 3 ml (with inhaler) | Inhalation by mouth | Penthrox (Combination Pack) | 6 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Metoclopramide | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection | Metoclopramide HCl Medsurge | 6 months stock by reference to usual demand |